The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.

The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.

A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.

Eli Lilly's retatrutide shows promise, helping obesity patients lose over 28% of their weight in a key trial.